Description: IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. It designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. The company offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma. It also provides Hummingbird ICP monitoring system comprising Hummingbird ICP Control Module (HICP200) and the related catheters, which include Hummingbird Quad ICP monitoring with drainage (H610), and Hummingbird Solo ICP monitoring (H110); and Hummingbird neuromonitoring products to manage patients suffering from conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and strokes. It markets and sells its products to hospitals through its direct sales force and a network of distribution partners. IRRAS AB (publ) was incorporated in 2011 and is headquartered in Stockholm, Sweden.
Home Page: www.irras.com
Vasagatan 16
Stockholm,
111 20
Sweden
Phone:
46 1 02 11 51 70
Officers
| Name | Title |
|---|---|
| Mr. Will Martin | Pres & CEO |
| Dr. Kleanthis G. Xanthopoulos Ph.D. | Exec. Director |
| Griffen Stapp | Group Financial Controller & Interim CFO |
| Mr. Sten Gustafsson | Director of Investor Relations |
| Ms. Kellie Fontes | Sr. Director of Human Capital |
| Dr. Niloufa Insanally | Head of Regulatory Affairs |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9362 |
| Price-to-Sales TTM: | 10.8623 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 47 |